Brief: Soligenix Announces Positive Clinical Results From A Comparative Study
25/06/2024 12:37
June 25 (Reuters) - Soligenix Inc SNGX.O :
* SOLIGENIX ANNOUNCES POSITIVE CLINICAL RESULTS FROM A
COMPARATIVE
STUDY EVALUATING HYBRYTE™ AGAINST VALCHLOR® IN THE TREATMENT OF
CUTANEOUS T-CELL LYMPHOMA
* SOLIGENIX: 1 OF 5 PATIENTS RECEIVING VALCHLOR HAD TO BE
WITHDRAWN FROM TRIAL DUE TO CLINICALLY SIGNIFICANT ALLERGIC
CONTACT DERMATITIS FROM VALCHLOR
* SOLIGENIX INC: DUE TO SMALL SAMPLE SIZE HYBRYTE RESULTS DO
NOT
ACHIEVE STATISTICAL SIGNIFICANCE IN STUDY
* SOLIGENIX INC: HYBRYTE WAS WELL TOLERATED IN ALL PATIENTS
Source text for Eikon: ID:nPn10fDm1a
Further company coverage: SNGX.O
((Reuters.Briefs@thomsonreuters.com;))